Corautus Genetics (Nasdaq: VEGF) is seeking to raise $25 million through a stock offering.

The company said Friday it would issue 6.5 million shares. Shares of Corautus closed down 34 cents on Friday at $3.86.

Lazard Capital Markets is the lead manager for the offering. Jeffries & Company will act as co-lead.

Corautus is currently involved in a clinical trial for a gene therapy project designed to help grow new blood vessels near the heart as a treatment for cardiovascular disease.

Corautus: www.corautus.com